RG-2833

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H25N3O2
Molecular Weight	339.4314
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N

InChI

InChIKey=VOPDXHFYDJAYNS-UHFFFAOYSA-N

InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C20H25N3O2
Molecular Weight	339.4314
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25159818 | https://www.ncbi.nlm.nih.gov/pubmed/20098685 | http://adisinsight.springer.com/drugs/800035788 | https://www.ncbi.nlm.nih.gov/pubmed/22901956

RG2833 is a compound originally developed by the Scripps Insitute for the treatment of Friedrick's Ataxia. RG2833 is a potent and selective inhibitor of neuronal histone deacetylase. RG2833 has been granted orphan drug status has been investigated in phase one clinical trials. There has also been proof of concept studies conducted for the treatment of Parkinson's disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histone deacetylase 3 35 Target ID: O15379 Gene ID: 8841.0 Gene Symbol: HDAC3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20098685	Inhibitor 8504		5.0 nM [Ki]
Histone deacetylase 1 51 Target ID: Q13547 Gene ID: 3065.0 Gene Symbol: HDAC1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20098685	Inhibitor 8504		32.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Friedreich ataxia 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25159818	Primary		Phase I 438	Unknown Approved Use Unknown
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22901956	Primary		Preclinical	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
1975 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2563 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6474 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10930 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7154 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
7758 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9715 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21973 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
35058 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39569 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25159818/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	RG-2833 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
120 mg 2 times / day multiple, oral Highest studied dose Dose: 120 mg, 2 times / day Route: oral Route: multiple Dose: 120 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25159818/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25159818/	Sources: https://pubmed.ncbi.nlm.nih.gov/25159818/

PubMed

Title	Date	PubMed
Epigenetic therapy for Friedreich ataxia.	2014-10	25159818
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.	2013-02	22901956
Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.	2010-01-21	20098685

Patents

Sample Use Guides

In Vivo Use Guide

Friedrick's ataxia patients were dosed in 4 cohorts, ranging from 30mg/day to 240mg/day of the formulated drug product of HDACi 109, RG2833. Patients were monitored for adverse effects as well as for increases in frataxin mRNA, frataxin protein, and chromatin modification in blood cells. RG2833 was delivered orally in capsules containing 30mg, 60mg, or 150mg of RG2833 free base equivalents as the active pharmaceutical ingredient and Ac-Di-Sol (2% croscarmellose sodium).

Route of Administration: Oral

In Vitro Use Guide

Unstimulated peripheral blood mononuclear cells were obtained from Friedreich Ataxia patients and incubated for 48 hours with RG-28833 at 1, 2.5, 5 or 10 microM. Frataxin mRNA from cells was measured by quantitative real-time RT-PCR in RNA. RG-2833 was highly effective demonstrating up to 9-fold upregulation of frataxin mRNA production with an almost linear dose-response relationship. The increase in frataxin gene expression was paralleled by increased histone acetylation.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:11:15 GMT 2025` Edited by `admin` on `Mon Mar 31 21:11:15 GMT 2025`
Record UNII	17V14R89EU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RG2833

Preferred Name

English

RG-2833

Common Name

English

RG 2833 [WHO-DD]

Common Name

English

RGFP-109

Code

English

N-(6-(2-AMINOPHENYLAMINO)-6-OXOHEXYL)-4-METHYLBENZAMIDE

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/10/793